Cardiff Oncology, Inc.
CRDF
$2.41
-$0.03-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.94M | -13.43M | -11.79M | -11.86M | -11.78M |
| Total Depreciation and Amortization | 229.00K | 228.00K | 96.00K | 101.00K | 240.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.38M | 1.23M | 1.05M | 1.10M | 1.05M |
| Change in Net Operating Assets | 4.00M | -816.00K | 378.00K | 202.00K | 1.26M |
| Cash from Operations | -8.33M | -12.79M | -10.27M | -10.46M | -9.23M |
| Capital Expenditure | -26.00K | -- | 0.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.96M | -14.58M | 4.51M | -9.43M | 14.02M |
| Cash from Investing | -4.98M | -14.58M | 4.51M | -9.43M | 14.02M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 3.00K | 44.19M | 7.43M | 2.06M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00 | 3.00K | 44.19M | 7.43M | 2.06M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.31M | -27.38M | 38.43M | -12.46M | 6.84M |